mercurius-adept schreef op 6 april 2021 15:16:
Zit nog even te kijken naar dat Jaarverslag 2020 van 30 maart jl, en vraag me af wat ze nou precies bedoelen met, of meer details over:
-R&D
"One further, positive, pivotal clinical trial will be required to support the approval of APD403 for CINV. Any further studies will be subject to raising sufficient additional finance to fund the trials."
-Forward: "Looking ahead, our priorities are to continue to fund the commercialisation of BARHEMSYS and BYFAVO and finance the company through to cash-flow positivity" "Additional financing, in the form or equity or debt, will
be necessary to continue to fund the commercial launch of our products and execute on our business plan"
er lijkt iig nog wat verwatering aan te komen